Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- JCO global oncology
- Publicado em
- 15 out 2025
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Review of All Solid Tumor Drug Approvals From 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency
Rafael Balsini Barreto, Mário Henrique Furlanetto Miranda, Camila Marchi Blatt, Bárbara Andressa Uliana, Denize Bodnar
Descritores MeSH
- Antineoplastic Agents
- Neoplasms
- Drug Approval
- Government Agencies
- Humans
- United States Food and Drug Administration
- United States
- Brazil
- Europe
Veja também
Estudos relacionados
- Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports
- Evolution of clinical benefit in cancer trials: comparing pivotal approval data with updated efficacy
- Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis
- Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review